Conclusions : This systematic review and meta- analysis showed that statin treatment significantly reduces systemic MDA concentrations .
Background : The effect of statins on oxidative stress markers , such as malondialdehyde ( MDA ) , is still a matter of debate .
We sought to address this issue by conducting a systematic review and meta- analysis of published data on the effect of statin treatment on systemic MDA concentrations .
The differential effect of statins on oxidative stress and endothelial function: atorvastatin versus pravastatin.
BACKGROUND Atherogenic risk in subjects with metabolic syndrome is partly mediated by increased oxidative stress and subsequent endothelial dysfunction . Clinical trials have demonstrated differences in outcomes between subjects receiving lipophilic statins ( atorvastatin ) compared with hydrophilic statins ( pravastatin ) . However , whether these findings are attributable to differences in the doses administered or to nonlipid-lowering pleiotropic effects of statins on oxidative stress and vascular function remains unknown . We hypothesized that equipotent doses of these two statins will have divergent effects on markers of oxidative stress and endothelial function . METHODS Thirty-six subjects with hyperlipidemia and metabolic syndrome and /or diabetes were r and omized in a double-blind manner to either pravastatin 80 mg or atorvastatin 10 mg daily .  Oxidative stress ( dROMs assay that measures lipid hydroperoxides , plasma thiobarbituric acid reactive substances [ TBARS ] , and aminothiol levels ) and brachial artery flow-mediated dilation ( FMD ) were measured at baseline and after 12 weeks of statin therapy . RESULTS Statin therapy reduced serum low-density lipoprotein cholesterol levels equally in both groups . Atorvastatin therapy was associated with a significant reduction in TBARS ( P = .006 ) and dROMs levels ( P = .02 ) , which was not observed in subjects treated with pravastatin .  Endothelial function improved with statin therapy ( P = .02 ) , but there was no difference between the statin groups . CONCLUSION In hyperlipidemic subjects with metabolic syndrome , atorvastatin is associated with a greater reduction in lipid markers of oxidation compared with pravastatin . Whether these effects are responsible for the outcome differences in trials comparing these agents needs further investigation
Conclusions : This systematic review and meta- analysis showed that statin treatment significantly reduces systemic MDA concentrations .
Background : The effect of statins on oxidative stress markers , such as malondialdehyde ( MDA ) , is still a matter of debate .
We sought to address this issue by conducting a systematic review and meta- analysis of published data on the effect of statin treatment on systemic MDA concentrations .